Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Kieran, C. Turner, J. Rubin, S. Chi, M. Zimmerman, Christine Chordas, G. Klement, A. Laforme, A. Gordon, Amanda Thomas, D. Neuberg, T. Browder, J. Folkman (2005)
A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive CancerJournal of Pediatric Hematology/Oncology, 27
T. Nakagawa, F. Tanaka, T. Takata, K. Matsuoka, R. Miyahara, Y. Otake, K. Yanagihara, Masakazu Fukushimab, H. Wada (2002)
Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p‐stage I nonsmall‐cell lung cancerJournal of Surgical Oncology, 81
K. Yonekura, Y. Basaki, L. Chikahisa, S. Okabe, A. Hashimoto, K. Miyadera, K. Wierzba, Yuji Yamada (1999)
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.Clinical cancer research : an official journal of the American Association for Cancer Research, 5 8
N. Tanigawa, Y. Mizuno, T. Hashimura, K. Honda, K. Satomura, Y. Hikasa, O. Niwa, T. Sugahara, O. Yoshida, D. Kern (1984)
Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.Cancer research, 44 6
C. Köhne-Wömpner, P. Schöffski, H. Schmoll (1994)
Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation.Annals of oncology : official journal of the European Society for Medical Oncology, 5 Suppl 3
S. Noguchi, H. Koyama, J. Uchino, R. Abe, S. Miura, K. Sugimachi, K. Akazawa, O. Abe (2005)
Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 10
T. Akasu, Y. Moriya, Y. Ohashi, S. Yoshida, K. Shirao, S. Kodaira (2006)
Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.Japanese journal of clinical oncology, 36 4
M. Colleoni, L. Orlando, G. Sanna, A. Rocca, P. Maisonneuve, G. Peruzzotti, R. Ghisini, M. Sandri, L. Zorzino, F. Nolè, G. Viale, A. Goldhirsch (2006)
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.Annals of oncology : official journal of the European Society for Medical Oncology, 17 2
R. Kerbel, B. Kamen (2004)
The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 4
K. Pietras, D. Hanahan (2005)
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 5
E. Mitry (1990)
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.The New England journal of medicine, 323 3
H. Kato, Y. Ichinose, M. Ohta, E. Hata, N. Tsubota, H. Tada, Yohu Watanabe, H. Wada, M. Tsuboi, N. Hamajima, M. Ohta (2004)
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.The New England journal of medicine, 350 17
T. Kurokawa, Y. Matsuno, M. Noguchi, S. Mizuno, Yuiko Shimsato (1994)
Surgically Curable “Early” Adenocarcinoma in the Periphery of the LungThe American Journal of Surgical Pathology, 18
G. Klement, P. Bőhlen, R. Kerbel (2000)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.The Journal of clinical investigation, 105 8
V. Jordan (2003)
Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2
M. Colleoni, A. Rocca, M. Sandri, L. Zorzino, G. Masci, F. Nolè, G. Peruzzotti, C. Robertson, L. Orlando, S. Cinieri, F. Braud, G. Viale, A. Goldhirsch (2002)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.Annals of oncology : official journal of the European Society for Medical Oncology, 13 1
F. Kasumi, M. Yoshimoto, J. Uchino, R. Abe, Y. Nomura, K. Sugimachi, H. Nakazato, O. Abe (2003)
Meta-Analysis of Five Studies on Tegafur plus Uracil (UFT) as Post-Operative Adjuvant Chemotherapy for Breast CancerOncology, 64
Given such differences as relative tumor burden, the optimal dose and schedule for postoperative adjuvant chemotherapy of microscopic disease might be expected to differ significantly from therapy of advanced higher volume disease. We investigated this hypothesis by determining the optimal dose and schedule of the 5-FU pro-drug, UFT, for treatment of early versus later stage disease models of the Lewis lung carcinoma (LLC). Postoperative adjuvant therapy of early stage disease was modeled by intravenous injection of LLC cells and initiating therapy one day later, thus simulating the presence of micrometastases at the time of surgery. As a model of ‘late’ stage disease, a LLC fragment was implanted subcutaneously and UFT therapy was initiated when the tumor was firmly established and had grown to >5 mm in size. A number of UFT dosing protocols were evaluated such as short-term (daily, for 7 days) maximum tolerated dosing (MTD), e.g. 31 mg/kg/day, or a much longer-term (e.g., daily, for up to 60 days) repetitive dosing using doses such as 24 mg/kg/day (the MTD) or lower. The long-term consecutive administration of UFT at relatively low minimally toxic dose levels is a superior dosing regimen in the postoperative adjuvant chemotherapy model; in contrast, the short-term higher dose protocols were superior for treatment of more advanced, established cancer. In addition, the efficacy of UFT in an adjuvant setting is more effective when drug administration is continued for longer periods and when treatment is initiated at progressively earlier time points, after disease establishment.
Oncology Reports – Spandidos Publications
Published: Aug 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.